Emerging evidence points at a significant association and shared genetic traits between adult attention-deficit/hyperactivity disorder (ADHD) and cardiometabolic conditions such as Obesity, Type-2 Diabetes, and cardiovascular disease, which, when inadequately treated, can lead to adverse outcomes and significant costs to society. Various national guidelines on cardiometabolic disease already highlight the importance of concurrent psychiatric disorders, but there is a lack of knowledge around ADHD. This is problematic given that ADHD is a common and serious complex chronic condition among adults.
TIMESPAN is a stellar consortium led by international recognised leaders working together on an interdisciplinary basis, consisting of clinicians, epidemiologists, biostatisticians, geneticists and artificial intelligence computer scientists. A multidisciplinary approach using multi-source data from 10 countries in 4 continents will allow TIMESPAN to advance the clinical research and deliver new tools for data management, analytics and data collection that fits market needs (e.g. health authorities, health care systems and providers, pharmaceutical companies). One of our clinically relevant goals is to create personalised treatment goals for people with ADHD and co-occurring cardiometabolic diseases.
Our vision is to improve the lives of people with ADHD and co-occurring cardiometabolic diseases by updating consensus statements, providing recommendations for treatment guidelines and disseminating results widely to patients, clinicians and other stakeholders.